Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207090 · ClinicalTrials.gov registry record · Phase 1
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
A Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT00207090: Completed Phase 1 study of Neoplasms and Advanced Solid Tumors, sponsored by R-Pharm.
NCT00207090 is a Phase 1 study of Neoplasms and Advanced Solid Tumors that has completed, run by R-Pharm. The registered enrollment target is 19 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00207090, a Phase 1 study of Neoplasms and Advanced Solid Tumors, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.
Primary Outcome
Cmax was obtained directly from the concentration-time data.
Conditions Studied
Interventions
- DRUG Rifampin
- DRUG ixabepilone
Study Locations (1)
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
What the finished NCT00207090 record still lists
NCT00207090 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Rifampin is the first listed.
NCT00207090 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00207090 about?
NCT00207090 is a clinical study titled "Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer". The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.
What is the current status of trial NCT00207090?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-09. Estimated completion is 2008-11.
What conditions does trial NCT00207090 study?
This clinical trial studies the following conditions: Neoplasms, Advanced Solid Tumors.
What interventions are being tested in trial NCT00207090?
The interventions under investigation include: Rifampin (DRUG), ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00207090?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00207090 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00207090's enrollment target sits among peer trials
19 147th of 158 higher than 12 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia